The O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham is partnering with the GO2 Foundation for Lung Cancer in a study—together with Vanderbilt University Medical Center and Augusta University—to determine how to improve participation from Black communities in lung cancer clinical trials.
In its first clinical trial in patients with a hard-to-treat form of uterine cancer, a targeted drug that subjects tumor cells to staggering levels of DNA damage caused tumors to shrink in nearly one-third of patients, investigators at Dana-Farber Cancer Institute found.
The National Comprehensive Cancer Network has published new best practice recommendations for Management of COVID-19 infection in patients with cancer.
A comprehensive review by University of North Carolina researchers and colleagues of hundreds of publications, incorporating more than two dozen articles on prevention screening for lung cancer with low-dose spiral computed tomography, shows there are both benefits and harms from screening.
JScreen, a national public health initiative based out of Emory University School of Medicine’s Department of Human Genetics, has established a program that offers at-home testing for more than 60 cancer susceptibility genes associated with hereditary risks for breast, ovarian, prostate, colorectal, skin and other cancers.
A John Hopkins study suggests gaining a better understanding of physical frailty could eventually help people age more healthfully.
The National Comprehensive Cancer Network has published NCCN Guidelines for Histiocytosis.
A study led by Yale Cancer Center and Department of Neurology researchers demonstrated that a blood draw may be the first step in helping to discover tumor reactive immune or T cells to treat advanced melanoma.
UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell therapy, to reduce the severity of treatment side effects.
City of Hope scientists have combined a checkpoint inhibitor with an anti-parasitic drug, ivermectin, to treat triple-negative breast cancer in preclinical research.
